An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
Clinical trial NCT02970929 · COMPLETED
Trial details
- NCT number
- NCT02970929
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-31
- Primary completion
- 2019-01-29
- Enrollment
- 157
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.